Single-arm, open-label interventional study (n=20 planned, ACTUAL registry count=5) of psilocybin-assisted interpersonal therapy for treatment-resistant major depression; two psilocybin doses plus eight psychotherapy sessions.
Single-arm, open-label feasibility study integrating interpersonal psychotherapy (IPT) with two supervised psilocybin dosing sessions for people with treatment‑resistant major depressive disorder.
The 10‑week intervention comprises three IPT preparation sessions, two dosing/debriefing sessions, five integration sessions, and follow-up at week 18; antidepressant discontinuation and safety monitoring (ECG, labs, urine drug and pregnancy tests) are supervised by consultant psychiatrists.
Interpersonal psychotherapy integrated with two psilocybin dosing sessions (single-arm, open-label).
Two psilocybin dosing sessions integrated with IPT (no per-dose mg specified in registry fragment).
Eight IPT sessions (3 preparation, 2 dosing/debriefing, 5 integration) delivered alongside psilocybin.